Abstract

Until recently, treatment advances in acute myeloid leukemia (AML) had been slow since the 1970s. However, in the past few years, as the understanding of the pathophysiology of AML has advanced, numerous treatments have been approved by the U.S. Food & Drug Administration. This article reviews the mechanisms of action, indications, and clinical trial details for eight novel agents, as well as the current discussions surrounding monitoring minimal residual disease.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call